On the basis of this information, many pharmaceutical companies have pursued the development of MCHR1 antagonists for the treatment of obesity (for a recent review, see Johansson, 2011). This evidence concerns the gene MCHR1 and obesity due to melanocortin 4 receptor deficiency.